NH HEALTH: INSIDE INFORMATION DELAY IN PUBLICATION OF THE 2023 ANNUAL RESULTS;POSTPONEMENT OF BOARD MEETING;AND SUSPENSION OF TRADING
Express News | Novartis Health responds to temporary suspension of trading: release of annual report postponed
Novartis Health (06606.HK) received 33,000 additional shares of common stock from Invesco, worth approximately HK$643,000
On March 21, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on March 21, Invesco Advisers, Inc. (Invesco Advisers, Inc.) increased its share holdings of $33,000 in common shares at an average price of HK$19.4848 per share on March 18, worth about HK$643,000. After the increase in holdings, Invesco's latest shareholding was 32.074,900 shares, and the good position ratio increased from 6.99% to 7.00%. Photo Source: Stock Exchange Equity Disclosure What is equity disclosure? According to the requirements of the Hong Kong Stock Exchange, major shareholders (those holding 5% or more of the shares)
Novartis Health (06606.HK) plans to hold a board meeting on March 28 to consider and approve the annual results
Glonghui, March 18, 丨 Novartis Health (06606.HK) announced that the board of directors meeting will be held on March 28, 2024 (Thursday) to consider and approve (among other things) the results and announcements of the Company, its subsidiaries and consolidated affiliated entities for the year ended 31 December 2023, and to deal with other matters.
NH HEALTH: NOTICE OF BOARD MEETING
Invesco sold 92,500 common shares of Novartis Health (06606.HK) worth approximately HK$1,857,600
On March 7, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on March 7, Invesco Advisers, Inc. (Invesco Advisers, Inc.) sold $92,500 common shares worth approximately HK$1,8576 million on March 1 at an average price of HK$20.0827 per share. After the sale, Invesco's latest shareholding was 32.039 million shares, and the good position ratio dropped from 7.01% to 6.99%. Photo Source: Stock Exchange Equity Disclosure What is equity disclosure? According to the requirements of the Hong Kong Stock Exchange, major shareholders (those holding 5% or more of the shares
Financial Services Association Venture Capital Connect: In February, the domestic medical sector raised 4.1 billion yuan, down 42% month-on-month, with the highest amount of financing for innovative drugs
In February 2024, there were 80 private equity financing incidents in the domestic healthcare sector, a decrease of 27% from the previous month; the total amount of disclosed financing was about 4,066 billion yuan, a decrease of 42% from the previous month.
Changes in Hong Kong stocks | Minimally Invasive Brain Science (02172) rose more than 5%, leading medical device stock institutions optimistic about the future prospects of overseas expansion of domestic medical devices
The increase in medical device stocks increased in the afternoon. As of press release, Minimally Invasive Brain Science (02172) rose 6.46% to HK$9.4; Chunli Healthcare (01858) rose 4.61% to HK$9.31; Haohai Biotech (06826) rose 3.71% to HK$34.95; and Novi Health (06606) rose 2.35% to HK$18.28.
Changes in Hong Kong stocks | Novartis Health (06606) rose more than 11%. Last year's results continued to exceed expectations, and the volume and price of the three major products rose sharply
Novartis Health (06606) rose more than 11%. As of press release, it rose 11.19% to HK$17.68, with a turnover of HK$349.31 million.
Highlights of the morning brokerage meeting: Focus on opportunities to increase the localization rate of medical devices
At today's brokerage morning meeting, CICC believes that it is concerned about opportunities to increase the localization rate of medical devices; CITIC Construction Investment pointed out that the future of the cross-border e-commerce industry has great potential; and Guotai Junan said that it is concerned about undervalued consumption of blue-chip stocks.
Southwest Securities: Novartis Health (06606)'s 2023 performance continues to exceed expectations, and the volume of Changweiqing's benchmark hospitals can be expected
Novartis Health expects to turn a loss into a profit in the first year of 2023, with a total cash repayment of 1.42 billion yuan.
Novartis Health (06606.HK): Annual sales exceeded expectations and receivables continued to accelerate
Incident: The company issued a positive profit warning for 2023. As of December 31, 2023, the Group's total annual revenue is expected to reach RMB 2.01 billion, an increase of 164% over 2022, and cash payments are expected
Novartis Health's 2023 pre-profit private hospital channel becomes the main source of revenue
① In 2023, Novartis Health is expected to achieve revenue of 1,979 billion yuan - 2,050 billion yuan, a maximum increase of 168.2%; gross profit of 1,808 billion yuan - 1,873 billion yuan, a maximum increase of 190.0%. ② The annual sales revenue of “Chang Weiqing” is about 1,177 billion yuan to 1,210 million yuan, an increase of 230.6%-239.9%. Private hospitals are the largest source of revenue from clinical channels.
Changes in Hong Kong stocks | Novartis Health (06606) is expected to achieve gross profit of more than 5% after earnings, and is expected to achieve gross profit of over 1.8 billion yuan in 2023. The current year will achieve profit after tax
The Zhitong Finance App learned that Novartis Health (06606) rose by more than 5%. As of press release, it had risen 5.05% to HK$18.32, with a turnover of HK$9.402,900. According to the news, Novartis Health issued an announcement. According to the median financial data before the audit, as of December 31, 2023, the Group's total annual revenue reached RMB 2.01 billion, an increase of 164% over 2022, an increase of 26 times over 2020, and cash payments of over RMB 1.4 billion. The company achieved annual gross profit of RMB 1.84 billion, achieved profit after tax in the first year, group cash balance and specific financial assets
Selected announcements: China CITIC Bank's net profit last year increased 8% year on year; CIMC expects net profit to more than double last year
Nuohui Health is profitable, with an estimated annual gross profit of about 1,888 billion yuan to 1,883 billion yuan, an increase of 179.9% to 190% over the previous year; China Unicom's 5G users increased net month-on-month by 5.082 million in December last year.
Novartis Health (6606.HK): The 2023 performance continues to exceed expectations, and the volume of Changweiqing's benchmark hospitals can be expected
Event: The company released its 2023 earnings forecast. The company's revenue forecast for 2023 is 19.8-2.05 billion yuan (+158.9%-168.2%); gross profit forecast for 2023 is 18.1-18.7
New Horizon Health Forecasts Up to 168% Rise in 2023 Revenue
New Horizon Health (HKG:6606) expects a 158.9% to 168.2% year-over-year rise in revenue for the year ended Dec. 31, 2023, to between 1.98 billion yuan and 2.05 billion yuan. The developer of screening
Novartis Health (06606.HK): Total revenue is expected to increase by 158.9% to 168.2% year-on-year in 2023
On January 22, GLONGHUI Health (06606.HK) announced that the Group's total revenue for the year ended December 31, 2023 is expected to be between RMB 1,9788 million and RMB 2,0498 million, an increase of 158.9% to 168.2% over approximately RMB 764.4 million for the year ended December 31, 2022. The Group's gross profit forecast for the year ended 31 December 2023 will be between RMB 1,807.6 billion and RMB 1,873.2 billion, compared with approximately RMB 6 for the year ended 31 December 2022.
NH HEALTH: POSITIVE PROFIT ALERT
Zheshang Securities: What are the marginal changes and investment logic of the pharmaceutical sectors in 2023Q4?
The Zhitong Finance App learned that against the backdrop of high base figures for some products in the 2022 Q4 and 2023Q1 pharmaceutical sector, the bank is more optimistic about digesting undervaluation and investment opportunities with the logic of going overseas.
No Data